Coronary CTA Use in Emergency Department saves time and money

Reference: Goldstein JA, Chinnaiyan KM, Abidov A, et al. The CT-STAT (coronary computed tomographic angiography for systemic triage of acute chest pain patients to treatment) trial. J Am Coll Cardiol 2011; 58: 1414-22.

Using coronary computed tomographic angiography (CTA) as a screening tool for low-risk patients with chest pain in the emergency department achieves lower costs and faster diagnoses compared with myocardial perfusion imaging but does not sacrifice safety or accuracy, according to results of a randomized trial appearing in the September 27, 2011, issue of the Journal of the American College of Cardiology.

For the trial, researchers led by Gilbert L. Raff, MD, of William Beaumont Hospital (Royal Oak, MI), randomized 699 patients with low-risk acute chest pain (TIMI risk score ≤ 4; normal initial ECG and cardiac enzymes) to standard nuclear stress imaging or coronary CTA as an initial screen at 16 different emergency departments between June 2007 and November 2008.

Both groups had substantial portions of patients ruled out from having significant CAD (82.2% with CTA, 89.9% with nuclear stress imaging). In addition, 24 patients (6.7%) were referred for invasive coronary angiography after CTA, with 13 (3.6%) receiving subsequent revascularization (4 CABG, 9 PCI). After nuclear stress imaging, 21 patients (6.2%) went on to coronary angiography (P = 0.8 compared with CTA), with 8 (2.4%) subsequently receiving revascularization (8 PCI, 0 CABG; P = 0.34 compared with CTA with regard to total revascularizations). There were no CABG procedures in the stress imaging arm.

SOLACI.ORG

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...